Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC—A Brief Report
- Gregory J. Riely
- , Myung Ju Ahn
- , Jeffrey M. Clarke
- , Ibiayi Dagogo-Jack
- , Raymond Esper
- , Enriqueta Felip
- , Francesco Gelsomino
- , Jonathan W. Goldman
- , Maen Hussein
- , Melissa Johnson
- , Kristen A. Marrone
- , Daniel Morgensztern
- , Ernest Nadal
- , Marcelo V. Negrao
- , Michael Offin
- , Mariano Provencio
- , Suresh S. Ramalingam
- , Logan Roof
- , Rachel E. Sanborn
- , Egbert F. Smit
- Memorial Sloan-Kettering Cancer Center
- Duke University
- Massachusetts General Hospital
- Florida Cancer Specialists
- Vall d'Hebron Institute of Oncology
- University Hospital S. Orsola
- University of California at Los Angeles
- Sarah Cannon Research Institute
- Johns Hopkins University
- Washington University St. Louis
- Bellvitge Biomedical Research Institute
- University of Texas MD Anderson Cancer Center
- Hospital Universitario Puerta de Hierro Majadahonda
- Emory University
- Ohio State University
- Providence Cancer Institute
- Leiden University
- Pfizer
- Pfizer
- Dana-Farber Cancer Institute
Research output: Contribution to journal › Article › peer-review
9
Link opens in a new tab
Scopus
citations